Delivery of fibroblast growth factor 2 enhances the viability of cord blood-derived mesenchymal stem cells transplanted to ischemic limbs

Journal of Bioscience and Bioengineering

Volumn 111, Issue 5, 2011, Pages 584-589

  Bhang, Suk Ho ^a   Lee, Tae Jin ^b   La, Wan Geun ^a   Kim, Dong Ik ^c   Kim, Byung Soo ^a  

^a Seoul National University   (South Korea)

^b Hanyang University   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Angiogenesis; Cell survival; Cord blood derived mesenchymal stem cells; Fibroblast growth factor 2; Hindlimb ischemia

Indexed keywords

ANGIOGENESIS; CELL SURVIVAL; CORD BLOOD; FIBROBLAST GROWTH FACTOR 2; HIND LIMBS;

BLOOD; CELL CULTURE; CELL DEATH; DISEASE CONTROL; ELECTRIC IMPEDANCE; ENDOTHELIAL CELLS; FIBROBLASTS; HISTOLOGY; PEPTIDES; STEM CELLS;

TISSUE;

FIBRIN; FIBROBLAST GROWTH FACTOR 2; NERVE GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR B; PROTEIN NG 2; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL SURVIVAL; CELL TRANSPLANTATION; CELL VIABILITY; FEMALE; GEL; HUMAN; HUMAN CELL; LIMB ISCHEMIA; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SECRETION;

ANIMALS; APOPTOSIS; FEMALE; FETAL BLOOD; FIBRIN; FIBROBLAST GROWTH FACTOR 2; HINDLIMB; HUMANS; ISCHEMIA; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; MICE, NUDE; NEOVASCULARIZATION, PHYSIOLOGIC; PLATELET-DERIVED GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MUS;

EID: 79954946124     PISSN: 13891723     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiosc.2011.01.003     Document Type: Article

References (27)

1. Miranville A., Heeschen C., Sengenès C., Curat C.A., Busse R., Bouloumié A. Improvement of postnatal neovascularization by human adipose tissue-derived stem cells. Circulation 2004, 110:349-355.
2. Miyahara Y., Nagaya N., Kataoka M., Yanagawa B., Tanaka K., Hao H., Ishino K., Ishida H., Shimizu T., Kangawa K., Sano S., Okano T., Kitamura S., Mori H. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat. Med. 2006, 12:459-465.
3. Cho S.W., Gwak S.J., Kang S.W., Bhang S.H., Song K.W., Yang Y.S., Choi C.Y., Kim B.S. Enhancement of angiogenic efficacy of human cord blood cell transplantation. Tissue Eng. 2006, 12:1651-1661.
4. Zhang M., Methot D., Poppa V., Fujio Y., Walsh K., Murry C.E. Cardiomyocyte grafting for cardiac repair: graft cell death and antideath strategies. J. Mol. Cell. Cardiol. 2001, 3:907-921.
5. Heusch G., Schulz R. Features of short-term myocardial hibernation. Mol. Cell. Biochem. 1998, 186:183-185.
6. Hearse D.J. Myocardial protection during ischemia and reperfusion. Mol. Cell. Biochem. 1998, 186:174-177.
7. Tang Y.L., Tang Y., Zhang Y.C., Qian K., Shen L., Phillips M.I. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J. Am. Coll. Cardiol. 2005, 46:1339-1350.
8. Zhu W., Chen J., Cong X., Hu S., Chen X. Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells. Stem Cells 2006, 24:416-425.
9. Wisel S., Khan M., Kuppusamy M.L., Mohan I.K., Chacko S.M., Rivera B.K., Sun B.C., Hideg K., Kuppusamy P. Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1-[2, 3, 4-trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression. J. Pharmacol. Exp. Ther. 2009, 329:543-550.
10. Afanasiev S.A., Falaleeva L.P., Rebrova T.U., Suslova T.E., Popov S.V., Karpov R.S. Effect of stress-proteins on survival of bone marrow mesenchymal stem cells after intramyocardial transplantation against the background of postinfarction heart remodeling. Bull. Exp. Biol. Med. 2008, 146:111-115.
11. Suzuki K., Smolenski R.T., Jayakumar J., Murtuza B., Brand N.J., Yacoub M.H. Heat shock treatment enhances graft cell survival in skeletal myoblast transplantation to the heart. Circulation 2000, 102:216-221.
12. Bhang S.H., Kim J.H., Yang H.S., La W.G., Lee T.J., Sun A.Y., Kim G.H., Lee M., Kim B.S. Combined delivery of heme oxygenase-1 gene and fibroblast growth factor-2 protein for therapeutic angiogenesis. Biomaterials 2009, 30:6247-6256.
13. Kawanaka H., Takagi G., Miyamoto M., Tara S., Takagi I., Takano H., Yasutake M., Tabata Y., Mizuno K. Therapeutic angiogenesis by controlled-release fibroblast growth factor in a patient with Churg-Strauss syndrome complicated by an intractable ischemic leg ulcer. Am. J. Med. Sci. 2009, 338:341-342.
14. Song H., Kwon K., Lim S., Kang S.M., Ko Y.G., Xu Z., Chung J.H., Kim B.S., Lee H., Joung B., Park S., Choi D., Jang Y., Chung N.S., Yoo K.J., Hwang K.C. Transfection of mesenchymal stem cells with the FGF-2 gene improves their survival under hypoxic conditions. Mol. Cells 2005, 19:402-407.
15. Nimni M.E. Polypeptide growth factors: targeted delivery systems. Biomaterials 1997, 18:1201-1225.
16. Jeon O., Ryu S.H., Chung J.H., Kim B.S. Control of basic fibroblast growth factor release from fibrin gel with heparin and concentrations of fibrinogen and thrombin. J. Control. Release 2005, 105:249-259.
17. Yang S.E., Ha C.W., Jung M., Jin H.J., Lee M., Song H., Choi S., Oh W., Yang Y.S. Mesenchymal stem/progenitor cells developed in cultures from UC blood. Cytotherapy 2004, 6:476-486.
18. Bhang S.H., Lee Y.E., Cho S.W., Shim J.W., Lee S.H., Choi C.Y., Chang J.W., Kim B.S. Basic fibroblast growth factor promotes bone marrow stromal cell transplantation-mediated neural regeneration in traumatic brain injury. Biochem. Biophys. Res. Commun. 2007, 359:40-45.
19. Cho S.W., Moon S.H., Lee S.H., Kang S.W., Kim J., Lim J.M., Kim H.S., Kim B.S., Chung H.M. Improvement of postnatal neovascularization by human embryonic stem cell derived endothelial-like cell transplantation in a mouse model of hindlimb ischemia. Circulation 2007, 116:2409-2419.
20. Jeon O., Kang S.W., Lim H.W., Chung J.H., Kim B.S. Long-term and zero-order release of basic fibroblast growth factor from heparin-conjugated poly(L-lactide-co-glycolide) nanospheres and fibrin gel. Biomaterials 2006, 27:1598-1607.
21. Yang H.S., Bhang S.H., Hwang J.W., Kim D.I., Kim B.S. Delivery of basic fibroblast growth factor using heparin-conjugated fibrin for therapeutic angiogenesis. Tissue Eng. A 2010, 16:2113-2119.
22. Shaulian E., Resnitzky D., Shifman O., Blandino G., Amsterdam A., Yayon A., Oren M. Induction of Mdm2 and enhancement of cell survival by bFGF. Oncogene 1997, 15:2717-2725.
23. Nugent M.A., Iozzo R.V. Fibroblast growth factor-2. Int. J. Biochem. Cell Biol. 2000, 32:15-20.
24. Kardami E., Detillieux K., Ma X., Jiang Z., Santiago J.J., Jimenez S.K., Cattini P.A. Fibroblast growth factor-2 and cardioprotection. Heart Fail. Rev. 2007, 12:267-277.
25. Shi Y.H., Bingle L., Gong L.H., Wang Y.X., Corke K.P., Fang W.G. Basic FGF augments hypoxia induced HIF-1-alpha expression and VEGF release in T47D breast cancer cells. Pathology 2007, 39:396-400.
26. Barr M.P., Bouchier-Hayes D.J., Harmey J.J. Vascular endothelial growth factor is an autocrine survival factor for breast tumour cells under hypoxia. Int. J. Oncol. 2008, 32:41-48.
27. Nunez G., Paso L.D. Linking extracellular survival signals and the apoptotic machinery. Curr. Opin. Neurobiol. 1998, 8:613-618.